Abstract: The present disclosure relates to novel pharmaceutical compositions comprising recombinantly engineered probiotic bacteria that can be used, inter alia, in the treatment of gastrointestinal inflammatory diseases and epithelial barrier function disorders. The probiotic bacteria preferably contain a nucleic acid encoding the heterodimeric protein of SEQ ID NO:1 and 2, or homologous sequences thereof sharing at least 80% identity with said sequences. In some embodiments, the pharmaceutical compositions described herein have particular application in the treatment or prevention of disease states associated with abnormally permeable epithelial barriers as well as inflammatory bowel diseases or disorders.

Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3?-transgenic mice resist better to DSS-induced colitis after antibiotherapy.

Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for protecting oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide, and their use. The inventors showed that increasing concentration of the hReg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in composition of gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and the ROS scavenging activity, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that hReg3?-transgenic mice were better able to resist DSS-induced colitis after antibiotherapy.

Abstract: A nutraceutical composition including one or more sources of fiber, glutamine, one or more probiotics, one or more sources of omega-3, and one or more antioxidants, for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota. Also, a method for preventing and/or treating dysbiosis including a step of administering the nutraceutical composition to a patient in need thereof. Further, a three-part kit for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota.

Abstract: A sampling method using a sampling device (2) comprising a container (5) comprising a body (6) consisting of a soft pouch, and a lid (30), in which at least one among the container (5) and the lid (30) is provided with a discharging member (40) suitable for, in an open state, discharging at least one part of the gases contained in the internal space (7) of the body (6) of the container (5), wherein the sampling method comprises the steps consisting in: collecting a biological material in the body (6) of the container (5), and assembling the lid (30) on the neck (IO) of the container (5), and placing an internal space (7) of the body (6) of the container (5) under anaerobic conditions by placing the discharging member (40) in the open state, by compressing the body (6) of the container (5) and by placing the discharging member (40) in a closed state.

Abstract: The present invention relates to a method for preparing a fecal 5 micro biota sample of a donor subject. Said method includes the following steps: a) collecting at least one fecal microbiota sample from the donor subject; b) within a period of less than 5 minutes after collecting the sample, placing said sample obtained in step a) in an oxygen-tight collection device; c) mixing the sample obtained in step b) with at least one aqueous saline IO solution containing at least one cryoprotectant and/or a filling agent; d) optionally, filtering the mixture obtained in step c), in particular by means of a filter comprising pores having a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm; and e) storing the mixture obtained in step c) or d) by freezing said mixture at a temperature 15 of between ?15° C. and ?100° C. Steps b) to e) are carried out in anaerobiosis.

Abstract: A sampling method using a sampling device (2) comprising a container (5) comprising a body (6) consisting of a soft pouch, and a lid (30), in which at least one among the container (5) and the lid (30) is provided with a discharging member (40) suitable for, in an open state, discharging at least one part of the gases contained in the internal space (7) of the body (6) of the container (5), wherein the sampling method comprises the steps consisting in: —collecting a biological material in the body (6) of the container (5), and assembling the lid (30) on the neck (10) of the container (5), —and placing an internal space (7) of the body (6) of the container (5) under anaerobic conditions by placing the discharging member (40) in the open state, by compressing the body (6) of the container (5) and by placing the discharging member (40) in a closed state.

Abstract: The present invention relates to a method for preparing a fecal 5 microbiota sample of a donor subject. Said method includes the following steps: a) collecting at least one fecal microbiota sample from the donor subject; b) within a period of less than 5 minutes after collecting the sample, placing said sample obtained in step a) in an oxygen-tight collection device; c) mixing the sample obtained in step b) with at least one aqueous saline 10 solution containing at least one cryoprotectant and/or a filling agent; d) optionally, filtering the mixture obtained in step c), in particular by means of a filter comprising pores having a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm; and e) storing the mixture obtained in step c) or d) by freezing said mixture at a temperature 15 of between ?15° C. and ?100° C. Steps b) to e) are carried out in anaerobiosis.

Abstract: The invention concerns a Reg3? polypeptide (also known as Hepatocarcinoma-Intestine-Pancreas/Pancreatitis Associated Protein (HIP/PAP)) for use in the protection of oxygen sensitive gram-positive bacteria, compositions comprising the polypeptide and their use. The inventors have shown that an increase in the concentration of the h Reg3? lectin into the gastrointestinal tract (GIT) lumen of hReg3?-transgenic mice induced significant changes in the composition of the gut microbiota, and dramatically improved host resistance to intestinal inflammation. hReg3? exerted a potent antioxidant activity on intestinal epithelial cells during colitis, and in particular the ROS scavenging activity, in particular, by promoting the survival of highly oxygen sensitive bacteria. Inventors also showed that h Reg3?-transgenic mice resist better to DSS-induced colitis after antibiotherapy.

Abstract: Method for lyophilisation of a simple of fecal microbiota. The present invention relates to a method for lyophilisation of a sample of fecal microbiota from a donor subject, comprising the following steps: A) mixing of a sample of fecal microbiota from a donor subject with a diluent selected from polyols, disaccharides to pentasaccharides, maltodextrins and mixtures thereof, and B) freezing the mixture obtained in A) at a temperature of less than ?50° C., preferably of between ?70° C. and ?100° C., followed by the lyophilisation thereof.

Abstract: Method for lyophilisation of a simple of fecal microbiota. The present invention relates to a method for lyophilisation of a sample of fecal microbiota from a donor subject, comprising the following steps: A) mixing of a sample of fecal microbiota from a donor subject with a diluent selected from polyols, disaccharides to pentasaccharides, maltodextrins and mixtures thereof, and B) freezing the mixture obtained in A) at a temperature of less than ?50° C., preferably of between ?70° C. and ?100° C., followed by the lyophilisation thereof.

Abstract: A sampling method using a sampling device (2) comprising a container (5) comprising a body (6) consisting of a soft pouch, and a lid (30), in which at least one among the container (5) and the lid (30) is provided with a discharging member (40) suitable for, in an open state, discharging at least one part of the gases contained in the internal space (7) of the body (6) of the container (5), wherein the sampling method comprises the steps consisting in:—collecting a biological material in the body (6) of the container (5), and assembling the lid (30) on the neck (10) of the container (5),—and placing an internal space (7) of the body (6) of the container (5) under anaerobic conditions by placing the discharging member (40) in the open state, by compressing the body (6) of the container (5) and by placing the discharging member (40) in a closed state.

Abstract: The present invention relates to a method for preparing a fecal 5 microbiota sample of a donor subject. Said method includes the following steps: a) collecting at least one fecal microbiota sample from the donor subject; b) within a period of less than 5 minutes after collecting the sample, placing said sample obtained in step a) in an oxygen-tight collection device; c) mixing the sample obtained in step b) with at least one aqueous saline 10 solution containing at least one cryoprotectant and/or a filling agent; d) optionally, filtering the mixture obtained in step c), in particular by means of a filter comprising pores having a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm; and e) storing the mixture obtained in step c) or d) by freezing said mixture at a temperature 15 of between ?15° C. and ?100° C. Steps b) to e) are carried out in anaerobiosis.

Abstract: The invention relates to markers for Crohn's disease and to specific compounds for detecting said markers. The invention also relates to methods for detecting, diagnosing and monitoring the progression of Crohn's disease as well as to methods for evaluating the efficacy of a treatment for said disease, and to compositions and kits that can be used for implementing said methods.

Abstract: The invention relates to the use of a strain of Lactobacillus rhamnosus for preventing or treating pathologies associated with an excessive accumulation of body fat. This strain is preferably administered orally, in particular in the form of a food or a food supplement.

Abstract: The present invention relates to a method for determining whether an overweight subject has a reduced gut bacterial diversity. The said method comprises detecting the presence or absence in a gut DNA sample of at least one gene of at least one bacterial species of Table 1 or Table 2, respectively.